Table 1.
Summary of IGF1R Inhibitor Clinical Trials
| Author/Year | Treatment | Phase | Advanced Malignancy | ORR (CR + PR)a | SDb |
|---|---|---|---|---|---|
| Atzori et al, 2011 (25) | Dalotuzumab | I | Solid tumors | 0% | 8% |
| Reidy-Lagunes, 2012 | Dalotuzumab | I | Neuroendocrine tumors | 0% | NR |
| Brana, 2014 | Dalotuzumab + MK-2206, ridaforolimus, or MK-0752 | I | Solid tumors | 0%/0%/0% | 37%/50%/0% |
| Doi, 2013 | Dalotuzumab + cetuximab and irinotecan | I | Colorectal | 15% | NR |
| Ellis, 2014 | Dalotuzumab + cisplatin and etoposide | I | SCLC | 67% | 17% |
| Di Cosimo et al, 2015 (26) | Dalotuzumab + ridaforolimus | I | Solid tumors | 7% | 46% |
| Moran et al, 2014 (32) | Dalotuzumab + erlotinib | I/II | NSCLC | 3% | 57% |
| Olmos et al, 2010 (19) | Figitumumab | I | Sarcoma | 7% | 29% |
| Haluska et al, 2007 (17) | Figitumumab | I | Solid tumors | 0% | 67% |
| Haluska et al, 2010 (18) | Figitumumab | I | Adrenocortical carcinoma | 0% | 57% |
| Juergens, 2011 | Figitumumab | I/II | Ewing sarcoma | 14% | 24% |
| Chi, 2012 | Figitumumab | II | Prostate | 94%c | NR |
| Becerra, 2014 | Figitumumab | II | Colorectal | 0% | NR |
| Schmitz, 2012 | Figitumumab | II | HNSCC | 0% | 12% |
| Goto, 2012 | Figitumumab + carboplatin and paclitaxel | I | NSCLC | 39% | 44% |
| Karp et al, 2009 (20) | Figitumumab + carboplatin and paclitaxel | I | Solid tumors | 36% | 38% |
| Karp et al, 2009 (21)d | Figitumumab + carboplatin and paclitaxel | II | NSCLC | 54% | NR |
| Langer et al, 2014 (31) | Figitumumab + carboplatin and paclitaxel | III | Nonadeno-NSCLC | 33% | 37% |
| Lacy et al, 2008 (16) | Figitumumab + dexamethasone | I | Multiple myeloma | 33% | 48% |
| Molife and colleagues, 2010 (19) | Figitumumab + docetaxel | I | Solid tumors | 10% | 31% |
| de Bono, 2014 | Figitumumab + docetaxel and prednisone | II | Prostate | 52%e | NR |
| Scagliotti et al, 2015 (33) | Figitumumab + erlotinib | III | Nonadeno-NSCLC | 5% | 39% |
| Quek, 2011 | Figitumumab + everolimus | I | Sarcoma and solid tumors | 6% | 83% |
| Murakami, 2012 | Ganitumab | I | Solid tumors | 0% | 37% |
| Strosberg, 2013 | Ganitumab | II | Carcinoid and pancreas | 0% | 34% |
| Tap et al, 2012 (24) | Ganitumab | II | Ewing and desmoplastic | 6% | 49% |
| Robertson, 2013 | Ganitumab + exemestane or fulvestrant | II | Breast cancer | 8% | 35% |
| Cohn, 2013 | Ganitumab + FOLFIRI | II | Colorectal | 8% | 59% |
| Kindler, 2012 | Ganitumab + gemcitabine | II | Pancreas | 10% | 51% |
| Okusaka, 2014 | Ganitumab + gemcitabine | I | Pancreas | 0% | 80% |
| Van Cutsem, 2014 | Ganitumab + panitumumab | I/II | Colorectal | 22% | 61% |
| Rosen, 2012 | Ganitumab + sorafenib, panitumumab, erlotinib, or gemcitabine | I | Solid tumors | 9% | 66% |
| Puzanov et al, 2015 (29) | Linsitinib | I | Solid tumors | 1% | 36% |
| Jones et al, 2015 (30) | Linsitinib | I | Solid tumors | 3% | 41% |
| Fassnacht et al, 2015 (35) | Linsitinib | III | Adrenocortical carcinoma | 3% | 32% |
| Bendell and colleagues, 2015 (26) | Linsitinib + everolimus | I | Colorectal | 0% | NR |
| Mahadevan, 2014 | R1507 | I | Solid tumors | 36% | 40% |
Abbreviations: CR, complete response; HNSCC, head and neck squamous cell carcinoma; NR, not reported; ORR, overall response rate; PR, partial response; SCLC, small-cell lung cancer; SD, stable disease. Data are from clinical trials investigating the efficacy of inhibition of the IGF1R in the treatment of various types of advanced malignancy.
a
CR and PR were determined by Response Evaluation Criteria In Solid Tumors criteria.
b
Duration of SD varied by study.
c
Partial response was measured by a greater than or +25% decrease in serum prostate-specific antigen.
d
Partial response was measured by decrease in prostate-specific antigen.
e
Study was retracted in 2012.